Does a Preservation Solution for Vascular Grafts Matter?

Slides:



Advertisements
Similar presentations
THE EVOLUTION OF EVH AND CONDUIT QUALITY
Advertisements

Allen Jeremias MD MSc, Sanjay Kaul MD, Luis Gruberg MD, Todd K. Rosengart MD, David L. Brown MD Divisions of Cardiovascular Medicine and Cardiothoracic.
Stents Are Not Enough: Statins Keith Channon Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford.
Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
Coronary Revascularisation in Patients With Diabetes Mellitus Dr Rod Stables The Cardiothoracic Centre Liverpool UK.
Can we prevent stent restenosis after coronary stent implantation
FFR vs Angiography for Multivessel Evaluation
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
CABG GUIDELINES SANJAY DRAVID, M.D.. INTRODUCTION ACC/AHA GUIDELINE UPDATE FOR CORONARY ARTERY BYPASS GRAFT SURGERY (JACC 2004; 44: AND CIRCULATION.
C.H.T Dr.Salarifar 1 Tehran Heart Center Tehran University of Medical Sciences PCI VS CABG M. SALARIFAR, MD.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
New ESC/EACTS guidelines on myocardial revascularisation Indications for coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention.
New guidelines for CABG
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
Preservation Solutions, Vein Graft Patency, and Outcomes after Coronary Bypass Surgery RE Harskamp, JH Alexander, PJ Schulte, CM Brophy, MJ Mack, ED Peterson,
Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.
Coronary Artery Disease in Diabetic Patients, Different from Non-diabetics?
Configurations of Arterial Grafts : When to use a SV Graft
Stent or Surgery: What is Best for a Woman ? Dr R H Stables Cardiothoracic Centre Liverpool UK.
Ongoing Trials in Managing Myocardial Ischemia. MERLIN-TIMI 36: Study design IV/oral ranolazinePlacebo Patients with non-ST elevation ACS treated with.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
Disclosures The presenter has no financial involvement with the product or competing products being discussed. The presenter received travel and lodging.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Review of an article Not all Angiotension-Converting Enzyme (ACE) inhibitors are Equal: Focus on Ramipril and Perindopril DiNicolantonio J, Lavie C, O’Keefe.
CABG versus PCI for Lmain/3 V-D: SYNTAX trial 3 year
M Gaudino. 2 Loop FD et al NEJM 1986 Arterial conduits used for coronary artery bypass grafting - Internal Thoracic Artery - Radial Artery - Right.
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
STICH CABG Objective To determine whether surgery plus medical management or medical management alone improve outcomes in CABG patients Study Design 1212.
Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme IMAGINEIMAGINE Presented at The European Society of.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.
Women reaching equality in health, despite the differences Nowadays women remain the largest CAD population subgroup being under-diagnosed and under-treated.
Lund – Malmö, SWEDEN. Is the Era of Off-pump Surgery over? ARASH MOKHTARI, MD, PHD.
 Hiroshima, Japan), 2010 and July 2012, the new shunt tube was used in 100 consecutive patients undergoing OPCABG new coronary shunt tube was easily.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.
CABG IN DIABETICS DR. SEYED SAEED FARZAM. Introduction Patients with diabetes mellitus Increased incidence of CAD More extensive disease at angiography.
Circ Res.2003;93:e98-e103 R2 이홍주. HMG-CoA reductase inhibitors (statins) - beneficial therapeutic effects in patients at risk for cardiovascular events.
Survival Benefits in Higher Risk Patients Coronary Revascularization has Revolutionized the Therapy of Ischemic Heart Disease Acute coronary syndromes.
Shengshou Hu M.D. National Center for Cardiovascular Disease,China
Revascularization in Patients With Left Ventricular Dysfunction:
The Evidence For Conduit Choice
Fig. 1 Clinical model of coronary collateral flow
The Winking Saphenous Vein Graft: Acute Aorto-Vein Graft Anastomotic Torsional Kink causing Dynamic Systolic Compression Complicating Vein Graft PCI Dr.
RAAS Blockade: Focus on ACEI
Jeff Macemon Waikato Cardiothoracic Unit
TAXUS II and IV: two-year follow-up
Section 5: Intervention and drug therapy
American College of Cardiology Presented by Dr. Stephan Windecker
Clopidogrel Reduces ADP-Induced Expression of Platelet-derived CD40L
The coronary artery bypass conduit: I
Fractional flow reserve–guided coronary artery bypass grafting: Can intraoperative physiologic imaging guide decision making?  T. Bruce Ferguson, MD,
The Circulatory System
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Why surgery won the SYNTAX trial and why it matters
LRC-CPPT and MRFIT Content Points:
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Correlation between endothelial function and hypertension
Disruption of Graft Endothelium Correlates With Early Failure After Off-Pump Coronary Artery Bypass Surgery  Jeffrey V. Manchio, BS, Junyan Gu, MD, Linda.
Multi-photon microscopic evaluation of saphenous vein endothelium and its preservation with a new solution, GALA  Hemant S Thatte, PhD, Kunda S Biswas,
Glenn N. Levine et al. JACC 2011;58:e44-e122
NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.
Surgical revascularization for coronary artery disease: are we about to surrender or cross the chasm?  Hani Shennib, MD  The Annals of Thoracic Surgery 
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

Does a Preservation Solution for Vascular Grafts Matter?

In the SYNTAX Trial (1800 patients with 3-vessel or left main CAD randomized to CABG or PCI (in a 1:1 ratio), rates of MACCE at 12 months were significantly higher in the PCI group (17.8%, vs. 12.4%, P = 0.002) (Serruys NEJM 2009). 5-year results of SYNTAX in patients with 3-vessel CAD concluded that CABG should remain the standard of care; it significantly lower rates of death, MI, and repeat revascularization, while stroke rates were similar (Head, European Heart J 2014). CABG has the most solid evidence from recent RCTs supporting its role in revascularization for stable CAD CABG has the most solid evidence from recent RCTs supporting its role in revascularization for stable CAD (Ferguson, Jr., Future Cardiol 2014) PCI impairs endothelial function; it only treats ‘SUITABLE’ localized proximal ‘culprit’ lesions but has NO PROPHYLACTIC BENEFIT against new disease.

In vitro data suggest that intraoperative preservation solutions may influence endothelial function and SVG failure after CABG. Data from the PREVENT IV study showed that CABG pts. whose SVG were preserved in a buffered solution like DuraGraft had lower SVG failure rates and trends toward better long-term clinical outcomes compared with pts. whose SVG were preserved in saline- or blood-based solutions (Harskamp, JAMA Surgery 2014). Despite the fact that the efficacy of CABG is limited by SVG failure, this continues to be the most used vascular graft (Harskamp, Ann Surg 2013).

Multi-photon imaging of SVG from CABG pts. showed that within minutes of storage in a standard preservation solution (e.g. saline- or blood-based), Ca mobilization and NO generation as a marker for EC function were markedly diminished with >90% of EC no longer viable in the vein. In contrast, SVG could be stored for 24 hours without substantial loss in cell viability in the newly formulated heparinized physiologic buffered salt solution GALA (DuraGraft) containing glutathione, ascorbic acid, and L-arginine (Thatte, Ann Thorac Surg 2003) EC= Endothelial cells. Green fluorescence indicates cell viability; red fluorescence indicates compromised cells. Heparinized lidocaine saline (HLS), autologous heparinized blood (AHB), tissue culture medium (TCM), Hank’s balanced salt solution (HBSS), and GALA (DuraGraft). Lack of EC integrity was observed after short-term storage in HLS, AHB, and TCM. EC viability was well preserved only in short-term storage in HBSS. EC remained viable in SV preserved in GALA up to 24 hours. A graft preservation solution that maintains functional/structural viability of endothelium improves long-term patency (Harskamp, Ann Surg 2014).

DURAGRAFT is not just a buffered solution, but also has glutathione, ascorbic acid and L-arginine that help preserve the integrity and function of the endothelium of both venous and arterial grafts Standard solutions in clinical use today both saline- and blood-based lead to profound decline in conduit viability. [Cardiovascular Res (Suppl.) 2014] Even short-time storage in physiologic saline solution (acidic pH of 5.5) significantly impairs endothelial vascular function (Wilbring, Eur J Cardiothorac Surg 2011). Once outside the circulation, blood loses its protective effects. Due to decrease in pCO2 ex vivo, there is a rapid loss of CO2 from the blood leading to increase in pH as high as 8.0. Alkaline pH affects the EC and SMC function due to loss of ionic balance [Thatte, JAMA Surgery (Letter) 2014]. The three key ingredients added to the GALA solution (DuraGraft) were chosen because of their putative effect on endothelial cell function The three key ingredients added to the GALA solution (DuraGraft) were chosen because of their putative effect on endothelial cell function (Thatte, Ann Thorac Surg 2003) Glutathione Glutathione as a cellular reducing agent has been found to increase L-arginine transport in EC and may lead to the stimulation of eNOS activity, nitric oxide generation, and coronary vasodilatation. Ascorbic acid Ascorbic acid is an antioxidant known to scavenge reactive oxygen species and also increases eNOS activity by preserving endothelium-derived nitric oxide bioactivity. L-arginine L-arginine is a known substrate of nitric oxide synthase and has been shown to decrease neutrophil-endothelial cell interactions in inflamed vessels.

DuraGraft A Preservation Solution for Vascular Grafts Like DuraGraft Really Matters